Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights

Iressa Follow-up Trial

Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information

Basic Trial Information

Phase
Type
Status
Age
Sponsor
Protocol IDs

Phase III

Natural history/Epidemiology, Treatment

Active

18 and over

Pharmaceutical / Industry

1839IL/0555
D7913L00008, NCT00357734

Trial Description

Summary

The purpose of this study is to assess the long-term safety profile and the secondary objective to estimate clinical benefit of ZD1839 (gefitinib).

Eligibility Criteria

Inclusion Criteria:

Provision of written informed consent to participate in the trial.

Female or male aged 18 years and over.

Patients with previously diagnosed cancer who have been treated with ZD1839 in a parent ZD1839 clinical trial and may benefit from continuation

Exclusion Criteria:

Known severe hypersensitivity to ZD1839

Concomitant use of phenytoin, carbamazepine, rifampicin, barbiturates, or St John's Wort.

Withdrawal from a parent ZD1839 trial because of tumor progress

Trial Contact Information

Trial Lead Organizations/Sponsors

AstraZeneca Pharmaceuticals LP

AstraZeneca Germany Medical Director, MD

Study Director

AstraZeneca Germany Clinical Study Information		Ph: +49 - (0)4103 - 708 3648
		Email: Manfred.Klevesath@astrazeneca.com

Trial Sites

Germany

Berlin

Research Site

Gauting

Research Site

Großhansdorf

Research Site

Heidelberg

Research Site

Hemer

Research Site

Jena

Research Site

Minden

Research Site

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00357734
Information obtained from ClinicalTrials.gov on July 16, 2008

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.